Sio Gene Therapies, Inc. (SIOX) News

Sio Gene Therapies, Inc. (SIOX): $0.48

0.01 (+1.70%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

Add SIOX to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#342 of 416

in industry

Filter SIOX News Items

SIOX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest SIOX News From Around the Web

Below are the latest news stories about SIO GENE THERAPIES INC that investors may wish to consider to help them evaluate SIOX as an investment opportunity.

Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results

– Three-Month and Nine-Month Losses decline by 84.2% and 73.5%, respectively – Operating Cash Outflows for the Nine Months Ended December 31, 2022 decreased by $23.8 million or 56% versus the prior year period – $46.1 million of cash and cash equivalents as of December 31, 2022, a strong cash position as the Company prepares for liquidation and dissolution, subject to stockholder approval NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial

Yahoo | February 14, 2023

Sio Gene Therapies Inc. Announces Board Approval of Plan of Complete Liquidation and Dissolution

NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (Nasdaq:SIOX) today announced that its Board of Directors has determined, after extensive and careful consideration of potential strategic alternatives, that it is in the best interests of the Company and its shareholders to dissolve the Company and liquidate its assets, including its subsidiaries. "After evaluating the Company's strategic options, the Board of Directors unanimously concluded that it is in the best interests of

Yahoo | December 14, 2022

Sio Gene Therapies Announces Fiscal Second Quarter 2022 Financial Results

- Three-Month and Six-Month Losses decline by 85.5% and 65.3%, respectively - Operating Cash Outflows for the Six Months Ended September 30, 2022 decreased by $8.1 million or 37% versus the prior year period - Strong cash position with $49.86 million of cash and cash equivalents as of September 30, 2022, expected to provide cash runway beyond December 2023 NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal second qua

Yahoo | November 10, 2022

Sio Gene Therapies Announces Fiscal First Quarter 2022 Financial Results

— Strong cash position with $54.8 million of cash and cash equivalents as of June 30, 2022, expected to provide cash runway beyond August 2023 NEW YORK, N.Y. and DURHAM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal first quarter ended June 30, 2022. “Our financial results show the beneficial effects on operating expenses and cash resulting from the termination of the licenses to our three clinical-stage programs an

Yahoo | August 11, 2022

Sio Gene Therapies Announces Fiscal Year 2021 Year-End Financial Results

NEW YORK and DURHAM, N.C., June 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal year ended March 31, 2022. Fiscal Fourth Quarter Financial Summary For the fourth fiscal quarter ended March 31, 2022, research and development expenses were $12.6 million, an increase of $4.4 million compared to the prior year quarter. The current period increase was primarily related to increased AXO-AAV-GM1 clinical trial material manufacturing ex

Yahoo | June 14, 2022

We Think Sio Gene Therapies (NASDAQ:SIOX) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Yahoo | May 24, 2022

Sio Gene Therapies Provides Corporate Update

-Company Announces Termination of Licensing Agreement for GM1 and GM2 Gene Therapies with the University of Massachusetts-Company has engaged SVB Securities to advise it on a range of strategic alternatives to maximize stockholder value-Company had cash and cash equivalents of approximately $64 million at March 31, 2022; license termination and related headcount reduction lowers operating expenses significantly NEW YORK and DURHAM, N.C., April 27, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc.

Yahoo | April 27, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!